Anti-Human CD28 Recombinant Antibody (TGN1412)

Customer Review

There are currently no Customer reviews or questions for TAB-064LC. Click the button above to contact us or submit your feedback about this product.

Jessica Green
18.Jun,23

Great for CD28 Studies

The Anti-CD28 Therapeutic Antibody has been excellent for our CD28 studies. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

Michael Evans
23.Nov,22

Effective in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for CD28 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Sarah Davis
12.May,21

Consistent and Reliable

This antibody has proven to be consistent and reliable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for CD28 have been particularly beneficial.

Q&As

1. Is the anti-CD28 therapeutic antibody suitable for use in ELISA applications?

   A: Yes, the anti-CD28 therapeutic antibody (TAB-064LC) is suitable for use in ELISA applications. It has been validated for use in such assays and provides reliable detection of CD28.

2. What is the optimal dilution for using the anti-CD28 therapeutic antibody in Western blotting?

   A: The optimal dilution for using the anti-CD28 therapeutic antibody (TAB-064LC) in Western blotting is typically 1:500 to 1:2000. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

3. Can the anti-CD28 therapeutic antibody be used in immunofluorescence assays?

   A: Yes, the anti-CD28 therapeutic antibody (TAB-064LC) can be used in immunofluorescence assays. It provides specific binding to CD28, allowing for detailed visualization of its expression in cells.

4. Is the anti-CD28 therapeutic antibody effective in blocking CD28 interactions in vitro?

   A: Yes, the anti-CD28 therapeutic antibody (TAB-064LC) is effective in blocking CD28 interactions in vitro. It can inhibit the interaction between CD28 and its ligands, which is useful for studying immune signaling pathways involving CD28.

5. What are the recommended storage conditions for the anti-CD28 therapeutic antibody?

   A: The recommended storage condition for the anti-CD28 therapeutic antibody (TAB-064LC) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Ye, Chunting, et al. "A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic-related cytokine release syndrome." The FASEB Journal 34.9 (2020): 12963-12975. https://doi.org/10.1096/fj.202001203R
   This study presents a rapid, sensitive, and reproducible humanized mouse model for predicting cytokine release syndrome (CRS), a severe adverse event associated with immunotherapies. The researchers developed a platform based on NOD-scid IL2rγnull (NSG) mice engrafted with human peripheral blood mononuclear cells (PBMCs). They tested several mouse strains including NSG, NSG-SGM3 (expressing human stem cell factor, GM-CSF, and IL-3), and NSG-MHC-DKO (lacking MHC class I and II expression). The model successfully captured donor-specific variability in cytokine release following treatment with various immunotherapeutics, including anti-CD3, anti-CD28, anti-PD-1, and anti-thymocyte globulin. Importantly, the NSG-SGM3 strain demonstrated robust responses to a TGN1412 analog (anti-CD28 superagonist), reproducing the rapid cytokine storm observed in the infamous 2006 clinical trial that caused life-threatening conditions in healthy volunteers. The researchers validated that the cytokine release was drug-dependent, occurred in the absence of acute xenogeneic graft-versus-host disease, and was reproducible between experiments, making this model valuable for screening novel therapeutics for inflammatory events.
   Creative Biolabs contributed a TGN1412 analog (anti-CD28 superagonist) that was critical for validating the model's ability to predict severe CRS events that conventional preclinical testing had failed to identify. This reagent enabled the researchers to demonstrate that their humanized mouse model could detect potentially dangerous cytokine storms that weren't captured by previous in vitro assays or non-human primate studies.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-064LC, RRID: AB_3111785)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Related Diseases

Rheumatoid Arthritis

Systemic Lupus Erythematosus

Allograft Rejection

Autoimmune Thyroid Disease

Graft-versus-Host Disease

Maturity Onset Diabetes of the Young

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "Clone TGN1412"

See other products for "CD28"

Select a product category from the dropdown menu below to view related products.